ITRM20020620A1 - Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. - Google Patents

Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Info

Publication number
ITRM20020620A1
ITRM20020620A1 IT000620A ITRM20020620A ITRM20020620A1 IT RM20020620 A1 ITRM20020620 A1 IT RM20020620A1 IT 000620 A IT000620 A IT 000620A IT RM20020620 A ITRM20020620 A IT RM20020620A IT RM20020620 A1 ITRM20020620 A1 IT RM20020620A1
Authority
IT
Italy
Prior art keywords
carnitine
prevention
treatment
andropause
disorders caused
Prior art date
Application number
IT000620A
Other languages
English (en)
Italian (it)
Inventor
Giulio Biagiotti
Giorgio Cavallini
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000620A priority Critical patent/ITRM20020620A1/it
Priority to JP2004560181A priority patent/JP4767542B2/ja
Priority to CA2507429A priority patent/CA2507429C/en
Priority to AT03780642T priority patent/ATE422883T1/de
Priority to DK03780642T priority patent/DK1569635T3/da
Priority to SI200331543T priority patent/SI1569635T1/sl
Priority to PL378418A priority patent/PL211032B1/pl
Priority to KR1020057009768A priority patent/KR101039818B1/ko
Priority to PT03780642T priority patent/PT1569635E/pt
Priority to EP03780642A priority patent/EP1569635B1/en
Priority to MXPA05006072A priority patent/MXPA05006072A/es
Priority to DE60326262T priority patent/DE60326262D1/de
Priority to PCT/IT2003/000757 priority patent/WO2004054567A1/en
Priority to US10/535,509 priority patent/US7956091B2/en
Priority to ES03780642T priority patent/ES2322455T3/es
Priority to AU2003288739A priority patent/AU2003288739A1/en
Publication of ITRM20020620A1 publication Critical patent/ITRM20020620A1/it
Priority to US12/076,256 priority patent/US7776913B2/en
Priority to CY20091100492T priority patent/CY1109051T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000620A 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa. ITRM20020620A1 (it)

Priority Applications (18)

Application Number Priority Date Filing Date Title
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
EP03780642A EP1569635B1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
MXPA05006072A MXPA05006072A (es) 2002-12-13 2003-11-20 Usos de carnitinas para prevencion y/o tratamiento de trastornos provocados por la andropausia.
AT03780642T ATE422883T1 (de) 2002-12-13 2003-11-20 Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
DK03780642T DK1569635T3 (da) 2002-12-13 2003-11-20 Anvendelse af carnitiner til forebyggelse og/eller behandling af lidelser forårsaget af andropause
SI200331543T SI1569635T1 (sl) 2002-12-13 2003-11-20 Uporaba karnitinov za preventivo in/ali zdravljenje motenj povzroäśenih z andropavzo
PL378418A PL211032B1 (pl) 2002-12-13 2003-11-20 Zastosowanie propionylo-L-karnityny w zestawieniu z acetylo-L-karnityną lub ich farmaceutycznie dopuszczalnych soli do otrzymywania leku lub dodatku odżywczego
KR1020057009768A KR101039818B1 (ko) 2002-12-13 2003-11-20 남성 갱년기에 의해 유발되는 질환의 예방 및/또는 치료를위한 카르니틴의 용도
PT03780642T PT1569635E (pt) 2002-12-13 2003-11-20 Utilização de carnitinas para a prevenção ou o tratamento de distúrbios causados pela andropausa
JP2004560181A JP4767542B2 (ja) 2002-12-13 2003-11-20 男性更年期が原因の異常の予防および/または治療のためのカルニチンの使用
CA2507429A CA2507429C (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
DE60326262T DE60326262D1 (de) 2002-12-13 2003-11-20 Verwendung von carnitinen zur prävention und/oder behandlung von krankheiten die durch die andropause verursacht werden
PCT/IT2003/000757 WO2004054567A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
US10/535,509 US7956091B2 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
ES03780642T ES2322455T3 (es) 2002-12-13 2003-11-20 Uso de carnitinas para la prevencion y/o tratamiento de trastornos producidos por la andropausia.
AU2003288739A AU2003288739A1 (en) 2002-12-13 2003-11-20 Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
US12/076,256 US7776913B2 (en) 2002-12-13 2008-03-14 Carnitines for treating or preventing disorders caused by andropause
CY20091100492T CY1109051T1 (el) 2002-12-13 2009-05-07 Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Publications (1)

Publication Number Publication Date
ITRM20020620A1 true ITRM20020620A1 (it) 2004-06-14

Family

ID=32587900

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000620A ITRM20020620A1 (it) 2002-12-13 2002-12-13 Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.

Country Status (17)

Country Link
US (1) US7956091B2 (enExample)
EP (1) EP1569635B1 (enExample)
JP (1) JP4767542B2 (enExample)
KR (1) KR101039818B1 (enExample)
AT (1) ATE422883T1 (enExample)
AU (1) AU2003288739A1 (enExample)
CA (1) CA2507429C (enExample)
CY (1) CY1109051T1 (enExample)
DE (1) DE60326262D1 (enExample)
DK (1) DK1569635T3 (enExample)
ES (1) ES2322455T3 (enExample)
IT (1) ITRM20020620A1 (enExample)
MX (1) MXPA05006072A (enExample)
PL (1) PL211032B1 (enExample)
PT (1) PT1569635E (enExample)
SI (1) SI1569635T1 (enExample)
WO (1) WO2004054567A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272812A1 (en) * 2002-02-07 2005-12-08 Pettegrew Jay W Methor for use of acetyl-L-carnitine (ALCAR) for treatment of depressive disorders in humans
US7407778B2 (en) 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
EP1641806B1 (en) 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholine and its derivatives for medical imaging of neuropsychiatric disorders
ITRM20040561A1 (it) * 2004-11-11 2005-02-11 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina in combinazione con propionil l-carnitina e sildenafil per il trattamento della disfunzione erettile.
KR101460125B1 (ko) * 2013-02-05 2014-11-11 주식회사 바이오그랜드 루이보스 추출물을 유효성분으로 하는 남성 노화 및 갱년기 예방 및 개선용 조성물
WO2016167254A1 (ja) * 2015-04-17 2016-10-20 株式会社山田養蜂場本社 蜂の子を含有する滋養強壮剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
EP0681839A3 (en) 1994-05-12 1997-11-12 Hirohiko Kuratsune A pharmaceutical preparation comprising an acylcarnitine
IT1290801B1 (it) * 1996-07-05 1998-12-11 Mendes Srl Uso della acetil l-carnitina, della isovaleril l-carnitina, della propionil l-carnitina o dei loro sali farmacologicamente accettabili
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1295408B1 (it) * 1997-10-03 1999-05-12 Sigma Tau Ind Farmaceuti Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
IT1302125B1 (it) * 1998-08-03 2000-07-31 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed antiproliferativacomprendente una carnitina ed un carotenoide
IT1302307B1 (it) * 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
IT1306130B1 (it) * 1999-04-16 2001-05-30 Sigma Tau Healthscience Spa Composizione comprendente una carnitina e glutatione, atta adaumentare l'assorbimento del glutatione sinergizzandone gli effetti.
US6399116B1 (en) * 2000-04-28 2002-06-04 Rulin Xiu Rhodiola and used thereof
DE60216090T2 (de) * 2001-05-29 2007-05-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia

Also Published As

Publication number Publication date
PT1569635E (pt) 2009-05-11
JP2006511531A (ja) 2006-04-06
MXPA05006072A (es) 2005-09-30
US20060135606A1 (en) 2006-06-22
CA2507429C (en) 2012-09-04
KR20050084052A (ko) 2005-08-26
ES2322455T3 (es) 2009-06-22
DK1569635T3 (da) 2009-04-20
CA2507429A1 (en) 2004-07-01
EP1569635A1 (en) 2005-09-07
EP1569635B1 (en) 2009-02-18
ATE422883T1 (de) 2009-03-15
AU2003288739A1 (en) 2004-07-09
SI1569635T1 (sl) 2009-06-30
WO2004054567A1 (en) 2004-07-01
PL211032B1 (pl) 2012-04-30
US7956091B2 (en) 2011-06-07
JP4767542B2 (ja) 2011-09-07
PL378418A1 (pl) 2006-04-03
KR101039818B1 (ko) 2011-06-09
DE60326262D1 (de) 2009-04-02
CY1109051T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
CA2341973A1 (en) Antioxidant composition comprising acetyl l-carnitine and .alpha.-lipoic acid
CY1109051T1 (el) Χρηση καρνιτινων για την προληψη και/ή θεραπεια διαταραχων που προκαλουνται απο την ανδροπαυση
ATE99172T1 (de) Verwendung von acetyl-l-carnitin zur behandlung von katarakt, sowie pharmazeutische zusammensetzungen fuer eine derartige behandlung.
IT1295408B1 (it) Associazione di l-carnitina e alcanoil l-carnitine per il trattamento dell'alcoolismo
BR0010150A (pt) Solução oral de prucalopride
MX9703810A (es) Medicamento que comprende un derivado de carnitinapara tratar la enfermedad de alzheimer en pacientes con inicio prematuro.
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon
SG162836A1 (en) Use of a combination comprising l-carnitine or alkanoyl l-carnitine, lipid solubl benzoquinone and omega-3-polyunsaturated fatty acid for the preparation of a dietary supplement or medicament for the treatment of corneal diseases
PL378537A1 (pl) Zastosowanie propionylo L-karnityny do otrzymywania leku do leczenia glaukomii
BR0009676A (pt) Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica
BR0309055A (pt) Uso combinado de l-carnitina, acetil l-carnitina e propionil l-carnitina para o tratamento da oligoastenoteratospermia
CY1110576T1 (el) Χρηση της ακετυλ l-καρνιτινης για τη θεραπεια του ινομυαλγικου συνδρομου
ATE259778T1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
NO20044519L (no) Hyperforinderivater, anvendelse derav samt formuleringer som inneholder dem
WO2001064203A3 (en) Composition for the prevention and/or treatment of vascular diseases, comprising propionyl l-carnitine and coenzyme q¿10?
HUP0402118A3 (en) Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung
SI1937245T1 (sl) Spojina uporabna za preprečevanje in zdravljenjeleve ventrikularne hipertofije pri dializiranih pacientih
RU99123159A (ru) Средство для лечения перитонита
TW200420560A (en) Crystalline form
ITRM20010319A1 (it) Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.
ITRM20000688A0 (it) Uso della isovaleril l-carnitina per la preparazione di un medicamento per la prevenzione e cura dell'osteoporosi.
ITRM20010292A1 (it) Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
MX9304553A (es) Complejo de ibuprofen-beta-ciclodextrina para la fabricacion de unmedicamento de consumo oral, procedimiento para su preparacion ycomposiciones farmaceuticas que lo contienen.